Design Therapeutics, Inc. DSGN 深 滬
等待開盤 05-19 09:30:00 美东时间
10.70
0.000
0.00%
華盛通- 最 高--
- 今 開--
- 成交量 0股
- 最 低 --
- 昨 收 10.70
- 總市值 6.68亿
- 52周最高 17.25
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 3.33
- 委 比 0.00%
- 總股本 6245.70万
- 歷史最高 50.50
- 量 比 0
- 振 幅 0.00%
- 歷史最低 1.94
- 每 手 1
- 風險率 3.18%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Design Therapeutics shares are trading lower. The company announced biomarker and clinical data from the ongoing Phase 1/2 RESTORE-FA trial evaluating DT-216P2 in patients with Friedreich ataxia.
Design Therapeutics shares are trading lower. The company announced biomarker a...
05-18 22:42
Design Therapeutics reports positive Phase 1/2 DT-216P2 data
Design Therapeutics ( ($DSGN) ) has issued an update. On May 18, 2026, Design T...
05-18 19:53
Dole Posts Downbeat Q1 Earnings, Joins Ocular Therapeutix And Other Big Stocks Moving Lower In Monday's Pre-Market Session
U.S. stock futures down 0.1%, Dole PLC drops 5.9% after missing earning estimates, other stocks also decline in pre-market trading.
05-11 20:02
美股大行评级 | 潜在涨幅85%！SoFi获机构升目标价至49美元；华尔街大行看涨AMD至400美元
今日重点评级关注：Canaccord Genuity：维持Sagimet Biosciences"买入"评级，目标价从28美元升至49美元；HC Wainwright & Co.：维持Fate Therapeutics"买入"评级，目标价从5美元升至7美元
05-05 11:40
Oppenheimer Maintains Outperform on Design Therapeutics, Raises Price Target to $21
Oppenheimer analyst Kostas Biliouris maintains Design Therapeutics (NASDAQ:DSGN) with a Outperform and raises the price target from $18 to $21.
05-05 01:49
Design Therapeutics shares are trading higher after the company reported better-than-expected Q1 EPS results.
Design Therapeutics shares are trading higher after the company reported better...
04-30 00:06
U.S. RESEARCH ROUNDUP-Coca-Cola Co, Mondelez, Zeta Global Holdings
U.S. RESEARCH ROUNDUP-Coca-Cola Co, Mondelez, Zeta Global Holdings April 29 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Coca-Cola Co, Mondelez and Zeta Global Holdings Corp on Wednesday. HIGHLIGHTS * Coca-Cola Co KO.
04-29 16:01
Design Therapeutics Q1 EPS $(0.29) Beats $(0.34) Estimate
Design Therapeutics (NASDAQ:DSGN) reported quarterly losses of $(0.29) per share which beat the analyst consensus estimate of $(0.34) by 14.71 percent. This is a 6.45 percent increase over losses of $(0.31) per share
04-29 04:37
Design Therapeutics Announces First Quarter 2026 Financial Results and Recent Business Updates
Design Therapeutics reported Q1 2026 financial results, highlighting progress in its RESTORE-FA trial for Friedreich ataxia with DT-216P2, which aims to restore frataxin levels. The company also appointed Dr. David Shapiro to its board, enhancing clinical expertise, and reported $222.8 million in cash to support ongoing operations through 2029.
04-28 20:01
美股大行评级 | 能源股获大行青睐！美国铝业、康索尔能源、康菲石油、EOG能源等获上调目标价；多只航空股遭下调目标价
今日重点评级关注：HC Wainwright & Co.：维持Altimmune"买入"评级，目标价从12美元升至25美元；BTIG：维持Jade Biosciences"买入"评级，目标价从28美元升至39美元
03-17 11:45
